Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre,randomised, double-blind, non-inferiority trial

https://www.thelancet.com/action/showPdf?pii=S2468-1253%2826%2900114-7

Bottom line

This is one of the largest and most important aspirin prevention studies ever conducted in people with Lynch syndrome.

It suggests:

• ✅ Daily aspirin can help reduce the risk of Lynch syndrome–related cancers.
• ✅ 100 mg daily appears to provide similar protection to 600 mg for many people.
• ✅ 100 mg causes fewer side effects and much less serious bleeding.
• ⏳ The researchers will continue following participants for another five years, and those longer-term results should provide even stronger evidence about the best aspirin dose.